Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab ± capecitabine maintenance after docetaxel + bevacizumab in metastatic breast cancer
CTR20131087Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, capecitabine in breast cancer, sponsored by Roche. Started Nov 2014; status: completed.
02
Drugs
bevacizumabcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20131087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131087.